Research never stops

Pain and inflammation

Evotec has a strong portfolio and partnerships for novel pain and inflammation targets

Molecule(s) Indication 
(mechanism)
Partner Status Next milestone Commercials
EVT401 Inflammation
(P2X7 inhibitor)
CONBA Phase I/II Phase II start Up to € 60 m milestones, royalties
Various Endometriosis Bayer Pre-clinical Pre-clinical candidate € 12 m upfront, total value up to approx. € 580 m, royalties
ND Inflammation Second Genome Pre-clincial Start of Phase I Milestones, Royalties

Pain and inflammation

CONBA/EVT401

- read more

Bayer/Various

- read more